       Document 0122
 DOCN  M9470122
 TI    Treatment with interferon for genital HPV in HIV-positive and
       HIV-negative women.
 DT    9409
 AU    Semprini AE; Stillo A; Marcozzi S; Castagna C; Fiore S; Radaelli U;
       Department of Obstetrics and Gynecology, San Paolo Biomedical;
       Institute, University of Milan Medical School, Italy.
 SO    Eur J Obstet Gynecol Reprod Biol. 1994 Feb;53(2):135-7. Unique
       Identifier : AIDSLINE MED/94252455
 AB    The administration of interferons can be resorted to, either on its own
       or in combination with physical destruction methods, when the extent of
       genital HPV is widespread. Extensive genital HPV involvement is often
       seen in HIV-positive patients as a consequence of their
       immunodeficiency. The extension of these lesions may invalidate
       treatment by physical destruction, while an underlying immunodeficiency
       renders interferon therapy less efficacious. We studied HIV-positive and
       HIV-negative patients with a similar HPV involvement of their genital
       tract and compared the effectiveness of systemically administered alpha
       2b and beta interferons in clearing HPV. Our results confirm that
       interferon therapy will cure most patients with extensive genital HPV
       when they are HIV-negative. HIV-positive patients with CD4 counts over
       400 lymphocytes/mm3 may expect a similar cure rate, but this halves when
       this critical threshold is crossed. In these severely immunodeficient
       patients repeated courses of interferon therapy alone or in combination
       with physical destruction methods may be required to cure HPV infection.
 DE    Female  Genital Diseases, Female/COMPLICATIONS/*THERAPY  Human  *HIV
       Seronegativity  HIV Seropositivity/*COMPLICATIONS/PATHOLOGY
       Interferon-beta/*THERAPEUTIC USE  Interferon-gamma,
       Recombinant/THERAPEUTIC USE  Leukocyte Count  Papovaviridae
       Infections/COMPLICATIONS/*THERAPY  Tumor Virus
       Infections/COMPLICATIONS/*THERAPY  T4 Lymphocytes/PATHOLOGY  JOURNAL
       ARTICLE

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).

